How much revenue did AnGes generate this year?
AnGes has achieved a revenue of 152.99 M JPY this year.
AnGes Revenue 2024
AnGes Revenue
152.99 M JPY
Ticker
4563.T
ISIN
JP3127700007
WKN
779518
In 2024, AnGes's sales reached 152.99 M JPY, a 128.13% difference from the 67.06 M JPY sales recorded in the previous year.
The AnGes Revenue history
| YEAR | REVENUE (undefined JPY) | GROSS MARGIN (%) |
|---|---|---|
| 2023 | 0.15 | 12,71 |
| 2022 | 0.07 | -40,01 |
| 2021 | 0.06 | 11,58 |
| 2020 | 0.04 | 42,45 |
| 2019 | 0.33 | 73,31 |
| 2018 | 0.61 | 69,15 |
| 2017 | 0.37 | 51,24 |
| 2016 | 0.51 | 66,07 |
| 2015 | 0.43 | 58,22 |
| 2014 | 0.91 | 83,40 |
| 2013 | 0.49 | 73,30 |
| 2012 | 0.44 | 70,93 |
| 2011 | 0.24 | 66,64 |
| 2010 | 0.29 | 71,14 |
| 2009 | 0.59 | 88,36 |
| 2008 | 0.95 | 94,82 |
| 2007 | 1.72 | 100,00 |
| 2006 | 2.91 | 0,67 |
| 2005 | 2.43 | 0,80 |
| 2004 | 2.7 | 0,72 |
AnGes Revenue, EBIT, Net Income JP3127700007 · 779518
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into AnGes, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by AnGes from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects AnGes’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of AnGes. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into AnGes’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing AnGes’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on AnGes’s growth potential.
AnGes Revenue, EBIT and net profit per share
| Date | AnGes Revenue | AnGes EBIT | AnGes Net Income |
|---|---|---|---|
| 2023 | 152.99 M undefined | -11.97 B undefined | -7.44 B undefined |
| 2022 | 67.06 M undefined | -16.31 B undefined | -14.71 B undefined |
| 2021 | 64.15 M undefined | -15.63 B undefined | -13.68 B undefined |
| 2020 | 40 M undefined | -5.6 B undefined | -4.21 B undefined |
| 2019 | 326.76 M undefined | -3.27 B undefined | -3.75 B undefined |
| 2018 | 610.05 M undefined | -3.07 B undefined | -3 B undefined |
| 2017 | 365.18 M undefined | -3.29 B undefined | -3.76 B undefined |
| 2016 | 514.27 M undefined | -4.76 B undefined | -4.78 B undefined |
| 2015 | 430.15 M undefined | -4.17 B undefined | -4.14 B undefined |
| 2014 | 909.9 M undefined | -2.27 B undefined | -2.37 B undefined |
| 2013 | 491.3 M undefined | -1.36 B undefined | -1.41 B undefined |
| 2012 | 444.5 M undefined | -1.79 B undefined | -1.71 B undefined |
| 2011 | 243.4 M undefined | -2.1 B undefined | -1.82 B undefined |
| 2010 | 286.9 M undefined | -2.01 B undefined | -1.97 B undefined |
| 2009 | 585.7 M undefined | -2.61 B undefined | -2.92 B undefined |
| 2008 | 951.1 M undefined | -2.76 B undefined | -3.53 B undefined |
| 2007 | 1.72 B undefined | -2.04 B undefined | -1.73 B undefined |
| 2006 | 2.91 B undefined | -1.52 B undefined | -1.11 B undefined |
| 2005 | 2.43 B undefined | -1.97 B undefined | -1.91 B undefined |
| 2004 | 2.7 B undefined | -1.56 B undefined | -1.54 B undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 2.7 B JPY | -1.56 B JPY | -1.54 B JPY |
| 2005 | 2.43 B JPY | -1.97 B JPY | -1.91 B JPY |
| 2006 | 2.91 B JPY | -1.52 B JPY | -1.11 B JPY |
| 2007 | 1.72 B JPY | -2.04 B JPY | -1.73 B JPY |
| 2008 | 951.1 M JPY | -2.76 B JPY | -3.53 B JPY |
| 2009 | 585.7 M JPY | -2.61 B JPY | -2.92 B JPY |
| 2010 | 286.9 M JPY | -2.01 B JPY | -1.97 B JPY |
| 2011 | 243.4 M JPY | -2.1 B JPY | -1.82 B JPY |
| 2012 | 444.5 M JPY | -1.79 B JPY | -1.71 B JPY |
| 2013 | 491.3 M JPY | -1.36 B JPY | -1.41 B JPY |
| 2014 | 909.9 M JPY | -2.27 B JPY | -2.37 B JPY |
| 2015 | 430.15 M JPY | -4.17 B JPY | -4.14 B JPY |
| 2016 | 514.27 M JPY | -4.76 B JPY | -4.78 B JPY |
| 2017 | 365.18 M JPY | -3.29 B JPY | -3.76 B JPY |
| 2018 | 610.05 M JPY | -3.07 B JPY | -3 B JPY |
| 2019 | 326.76 M JPY | -3.27 B JPY | -3.75 B JPY |
| 2020 | 40 M JPY | -5.6 B JPY | -4.21 B JPY |
| 2021 | 64.15 M JPY | -15.63 B JPY | -13.68 B JPY |
| 2022 | 67.06 M JPY | -16.31 B JPY | -14.71 B JPY |
| 2023 | 152.99 M JPY | -11.97 B JPY | -7.44 B JPY |
AnGes stock margins JP3127700007 · 779518
The AnGes margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AnGes. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AnGes.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the AnGes's sales revenue. A higher gross margin percentage indicates that the AnGes retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the AnGes's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the AnGes's total revenue generated. When comparing the revenue margin year over year, investors can gauge the AnGes's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the AnGes. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the AnGes's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
AnGes Margin History
| AnGes Gross margin | AnGes Profit margin | AnGes EBIT margin | AnGes Profit margin |
|---|---|---|---|
| 2023 | 12.71 % | -7,822.67 % | -4,861.66 % |
| 2022 | -40.01 % | -24,320.76 % | -21,942.37 % |
| 2021 | 11.58 % | -24,358.89 % | -21,318.8 % |
| 2020 | 42.45 % | -13,999.18 % | -10,524.3 % |
| 2019 | 73.31 % | -1,000.74 % | -1,147.89 % |
| 2018 | 69.15 % | -502.46 % | -491.21 % |
| 2017 | 51.24 % | -900.56 % | -1,030.91 % |
| 2016 | 66.07 % | -926.24 % | -928.85 % |
| 2015 | 58.22 % | -969.88 % | -963.22 % |
| 2014 | 83.4 % | -249.91 % | -260.38 % |
| 2013 | 73.3 % | -277.47 % | -286.93 % |
| 2012 | 70.93 % | -401.66 % | -384.34 % |
| 2011 | 66.64 % | -863.06 % | -745.73 % |
| 2010 | 71.14 % | -700.7 % | -685.67 % |
| 2009 | 88.36 % | -445.77 % | -498.79 % |
| 2008 | 94.82 % | -289.81 % | -371.61 % |
| 2007 | 100 % | -118.58 % | -100.49 % |
| 2006 | 12.71 % | -52.3 % | -38.28 % |
| 2005 | 12.71 % | -81.09 % | -78.39 % |
| 2004 | 12.71 % | -57.9 % | -57.17 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 12.71 % | -57.9 % | -57.17 % |
| 2005 | 12.71 % | -81.09 % | -78.39 % |
| 2006 | 12.71 % | -52.3 % | -38.28 % |
| 2007 | 100 % | -118.58 % | -100.49 % |
| 2008 | 94.82 % | -289.81 % | -371.61 % |
| 2009 | 88.36 % | -445.77 % | -498.79 % |
| 2010 | 71.14 % | -700.7 % | -685.67 % |
| 2011 | 66.64 % | -863.06 % | -745.73 % |
| 2012 | 70.93 % | -401.66 % | -384.34 % |
| 2013 | 73.3 % | -277.47 % | -286.93 % |
| 2014 | 83.4 % | -249.91 % | -260.38 % |
| 2015 | 58.22 % | -969.88 % | -963.22 % |
| 2016 | 66.07 % | -926.24 % | -928.85 % |
| 2017 | 51.24 % | -900.56 % | -1,030.91 % |
| 2018 | 69.15 % | -502.46 % | -491.21 % |
| 2019 | 73.31 % | -1,000.74 % | -1,147.89 % |
| 2020 | 42.45 % | -13,999.18 % | -10,524.3 % |
| 2021 | 11.58 % | -24,358.89 % | -21,318.8 % |
| 2022 | -40.01 % | -24,320.76 % | -21,942.37 % |
| 2023 | 12.71 % | -7,822.67 % | -4,861.66 % |
AnGes Aktienanalyse
What does AnGes do?
AnGes Inc is a Japanese biotechnology company specializing in the development and commercialization of therapies for cardiovascular, immunology, and oncology disorders. The company was founded in 1999 by experienced scientist Dr. Ryuichi Morishita. AnGes' technology is based on the use of DNA plasmids to deliver genes into human cells. This method offers a high level of control and precision in modifying genetic material, with the potential to revolutionize biotherapy. The company has conducted several successful clinical studies and acquired multiple patents related to their technology. Overall, AnGes operates in three main areas: cardiovascular medicine, oncology, and immunology. The company distributes a range of products and solutions for these fields, including therapies for heart failure, angina, cancer, and autoimmune diseases. AnGes' most well-known product currently is Collategene, used for the treatment of angina. Collategene is a therapy consisting of a combination of DNA plasmids and a special gel injected into the arteries. The gel promotes the formation of new blood vessels, supplying oxygen and nutrients to damaged tissue, supporting the repair and regeneration of the heart muscle. Another important product from AnGes is HGFgene, used to treat heart failure and chronic wounds. HGFgene contains essential growth factors that stimulate the formation of new blood vessels and tissue regeneration, potentially improving heart function. In addition to these products, AnGes also offers solutions for oncology, including a therapy called Protransgene used for pancreatic cancer treatment. Protransgene contains specific DNA plasmids that produce tumor-specific antigens and stimulate the body's immune system to fight the tumor. In immunology, AnGes has developed a technology called NFkB-decoy, with the potential to treat various inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. NFkB-decoy consists of synthetic DNA plasmids introduced into inflammatory cells, with anti-inflammatory effects. Overall, AnGes Inc. has established itself as a leading provider of biotherapeutics in Japan and is currently expanding into the US market. The company has an impressive track record in clinical research and development of innovative therapy options with the potential to improve the lives of millions of people. AnGes ist eines der beliebtesten Unternehmen auf Eulerpool.com.Revenue Details
Understanding AnGes's Sales Figures
The sales figures of AnGes originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Year-to-Year Comparison
Analyzing AnGes’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Impact on Investments
Investors often scrutinize AnGes's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Interpreting Sales Fluctuations
Increases in AnGes’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Frequently Asked Questions about AnGes stock
How much was the turnover of the company AnGes compared to the previous year?
The revenue of AnGes has increased by 128.13% increased compared to the previous year.
What does revenue mean for investors?
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
Which factors influence the revenue of AnGes?
The revenue of AnGes is influenced by various factors, including the demand for its products and services, market conditions, and prices.
How is the revenue of AnGes measured?
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
How does an increase in sales affect investments?
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
What are the possible risks associated with a declining revenue?
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
Why is the sales revenue of AnGes so important for investors?
The revenue of AnGes is an important indicator of financial performance and attractiveness for investors.
What strategic measures can a company take to increase revenue?
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
How much dividend does AnGes pay?
Over the past 12 months, AnGes paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AnGes is expected to pay a dividend of 0 JPY.
What is the dividend yield of AnGes?
The current dividend yield of AnGes is .
When does AnGes pay dividends?
AnGes pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of AnGes?
AnGes paid dividends every year for the past 0 years.
What is the dividend of AnGes?
For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.
In which sector is AnGes located?
AnGes is assigned to the 'Health' sector.
Wann musste ich die Aktien von AnGes kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AnGes from 9/12/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.
When did AnGes pay the last dividend?
The last dividend was paid out on 9/12/2024.
What was the dividend of AnGes in the year 2023?
In the year 2023, AnGes distributed 0 JPY as dividends.
In which currency does AnGes pay out the dividend?
The dividends of AnGes are distributed in JPY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von AnGes
Our stock analysis for AnGes Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AnGes Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
